Tüberküloz
Synopsis
Tuberculosis (TB), caused by the Mycobacterium tuberculosis bacillus, is a contagious disease that leadingly contributes to respiratory infection deaths worldwide. Thanks to national TB control programs implemented in Turkey since 1918, the incidence of the disease shows a downward trend, reaching 14.1 per 100,000 in 2018 with an overall treatment success rate recorded at 84.6%. In tuberculosis, which most frequently presents with clinical symptoms such as fatigue, loss of appetite, weight loss, night sweats, cough, sputum, and chest pain, HIV positivity, a history of close contact, organ transplantation, and the use of immunosuppressive drugs are among the main risk factors. While the definitive diagnosis of the disease is established through bacteriological sputum examinations and culture, chest radiographs, nucleic acid amplification tests (NAAT), tuberculin skin tests (TST), and interferon-gamma release assays (IGRA) are also utilized during the diagnostic process. Under the Directly Observed Therapy (DOT) system, the treatment process is carried out using standard regimens consisting of a 2-month initial phase with 4 drugs (HRZE) and a 4-month continuation phase with 2 drugs (HR), while cases developing drug resistance are referred to equipped specialized centers. Extra-pulmonary organ involvement accounts for approximately 35% of cases, whereas disruptions occurred in TB notification and treatment services during the COVID-19 pandemic due to quarantine measures. Since these two respiratory-transmitted diseases exhibit similar symptoms, performing bi-directional screening, adhering to infection control measures, and ensuring the uninterrupted continuation of TB treatment are of paramount importance.
References
Rakel, Robert E. & Rakel, David P. (2019). Aile hekimliği. (Esra Saatçı, Çev. Ed.). Ankara: Güneş Tıp Kitebevi.
Kara, F. (2019). Tüberküloz tanı ve tedavi rehberi. (2). Ankara: T.C. Sağlık Bakanlığı.
T.C. Sağlık Bakanlığı (2017). Tüberküloz istatistikleri. (20/01/2021tarihinde https://hsgm.saglik.gov.tr/tr/tuberkuloz-istatistikler adresinden ulaşılmıştır).
World Health Organization (2020). Covid-19: Considerations for tuberculosis (TB) care. (15/02/2021 tarihinde https://www.who.int/docs/default-source/documents/tuberculosis/infonote-tb-covid-19.pdf adresinden ulaşılmıştır).
Stop TB Partnership (2020). the potentıal ımpact of the covıd-19 response on tuberculosıs ın hıgh-burden countrıes: a modellıng analysıs (10/02/2021 tarihinde http://www.stoptb.org/assets/documents/covid/TB%20and%20COVID19_Modelling%20Study_5%20May%202020.pdf adresinden ulaşılmıştır).
Goverment of India (2020). Annexure 1: Guidance note on Bi-directional TB-COVID screening and screening of TB among ILI/SARI cases. (25/02/2021 tarihinde https://tbcindia.gov.in/WriteReadData/l892s/60159559755DODDG_NTEP%20Rapid%20Response_Full.pdf adresinden ulaşılmıştır).